vs
Side-by-side financial comparison of ARDELYX, INC. (ARDX) and Honest Company, Inc. (HNST). Click either name above to swap in a different company.
ARDELYX, INC. is the larger business by last-quarter revenue ($94.5M vs $78.1M, roughly 1.2× Honest Company, Inc.). On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs -19.7%). Over the past eight quarters, ARDELYX, INC.'s revenue compounded faster (13.6% CAGR vs -8.4%).
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
The Honest Company, Inc. is an American digital-first consumer goods company, based in Los Angeles and founded by actress Jessica Alba, Christopher Gavigan, and Brian Lee. The company had $319 million in 2021 sales, and was valued at roughly $550 million as of February 2022. Carla Vernón, Chief Executive Officer, is one of the first Afro-Latina CEOs of a U.S. publicly traded company. The Honest Company has raised multiple rounds of venture capital, and went public via an initial public offeri...
ARDX vs HNST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.5M | $78.1M |
| Net Profit | $-37.6M | — |
| Gross Margin | — | 42.6% |
| Operating Margin | — | 56.6% |
| Net Margin | -39.8% | — |
| Revenue YoY | 27.5% | -19.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.15 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $94.5M | $78.1M | ||
| Q4 25 | $125.2M | $88.0M | ||
| Q3 25 | $110.3M | $92.6M | ||
| Q2 25 | $97.7M | $93.5M | ||
| Q1 25 | $74.1M | $97.3M | ||
| Q4 24 | $116.1M | $99.8M | ||
| Q3 24 | $98.2M | $99.2M | ||
| Q2 24 | $73.2M | $93.0M |
| Q1 26 | $-37.6M | — | ||
| Q4 25 | $-407.0K | $-23.6M | ||
| Q3 25 | $-969.0K | $758.0K | ||
| Q2 25 | $-19.1M | $3.9M | ||
| Q1 25 | $-41.1M | $3.3M | ||
| Q4 24 | $4.6M | $-809.0K | ||
| Q3 24 | $-809.0K | $165.0K | ||
| Q2 24 | $-16.5M | $-4.1M |
| Q1 26 | — | 42.6% | ||
| Q4 25 | 91.3% | 15.7% | ||
| Q3 25 | 96.4% | 37.3% | ||
| Q2 25 | 87.3% | 40.4% | ||
| Q1 25 | 83.4% | 38.7% | ||
| Q4 24 | 84.3% | 38.8% | ||
| Q3 24 | 84.0% | 38.7% | ||
| Q2 24 | 87.1% | 38.3% |
| Q1 26 | — | 56.6% | ||
| Q4 25 | 4.1% | -27.5% | ||
| Q3 25 | 4.2% | 0.3% | ||
| Q2 25 | -14.7% | 3.1% | ||
| Q1 25 | -49.0% | 2.6% | ||
| Q4 24 | 7.0% | -1.0% | ||
| Q3 24 | 2.3% | 0.1% | ||
| Q2 24 | -18.6% | -4.3% |
| Q1 26 | -39.8% | — | ||
| Q4 25 | -0.3% | -26.8% | ||
| Q3 25 | -0.9% | 0.8% | ||
| Q2 25 | -19.5% | 4.1% | ||
| Q1 25 | -55.5% | 3.3% | ||
| Q4 24 | 4.0% | -0.8% | ||
| Q3 24 | -0.8% | 0.2% | ||
| Q2 24 | -22.5% | -4.4% |
| Q1 26 | $-0.15 | $0.00 | ||
| Q4 25 | $-0.01 | $-0.21 | ||
| Q3 25 | $0.00 | $0.01 | ||
| Q2 25 | $-0.08 | $0.03 | ||
| Q1 25 | $-0.17 | $0.03 | ||
| Q4 24 | $0.01 | $-0.01 | ||
| Q3 24 | $0.00 | $0.00 | ||
| Q2 24 | $-0.07 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.1M | $90.4M |
| Total DebtLower is stronger | $203.5M | — |
| Stockholders' EquityBook value | $148.6M | $169.1M |
| Total Assets | $504.5M | $214.9M |
| Debt / EquityLower = less leverage | 1.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $238.1M | $90.4M | ||
| Q4 25 | $68.0M | $89.6M | ||
| Q3 25 | $42.7M | $71.5M | ||
| Q2 25 | $90.0M | $72.1M | ||
| Q1 25 | $30.8M | $72.8M | ||
| Q4 24 | $64.9M | $75.4M | ||
| Q3 24 | $47.4M | $53.4M | ||
| Q2 24 | $41.9M | $36.6M |
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | — | ||
| Q3 25 | $202.1M | — | ||
| Q2 25 | $201.4M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | $150.9M | — | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — |
| Q1 26 | $148.6M | $169.1M | ||
| Q4 25 | $166.9M | $169.7M | ||
| Q3 25 | $154.3M | $190.2M | ||
| Q2 25 | $139.5M | $187.0M | ||
| Q1 25 | $145.7M | $180.4M | ||
| Q4 24 | $173.3M | $174.3M | ||
| Q3 24 | $158.3M | $133.9M | ||
| Q2 24 | $147.0M | $129.7M |
| Q1 26 | $504.5M | $214.9M | ||
| Q4 25 | $501.6M | $225.4M | ||
| Q3 25 | $486.2M | $241.5M | ||
| Q2 25 | $466.8M | $249.0M | ||
| Q1 25 | $410.2M | $265.3M | ||
| Q4 24 | $435.8M | $247.4M | ||
| Q3 24 | $367.9M | $209.2M | ||
| Q2 24 | $343.5M | $200.2M |
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
HNST
Segment breakdown not available.
